Roivant Sciences Ltd. Files 8-K with Shareholder Vote and Financials
Ticker: ROIV · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1635088
Sentiment: neutral
Topics: 8-K, corporate-action, financials
TL;DR
Roivant filed an 8-K on 9/16 detailing shareholder votes and financials from 9/10.
AI Summary
Roivant Sciences Ltd. filed an 8-K on September 16, 2024, reporting on matters submitted to a vote of security holders and including financial statements and exhibits. The earliest event reported was on September 10, 2024. The company is incorporated in Bermuda and its principal executive offices are located in London, United Kingdom.
Why It Matters
This filing provides updates on shareholder decisions and financial information, which are crucial for investors to assess the company's performance and strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of corporate actions and financial information, not indicating any immediate operational or financial distress.
Key Players & Entities
- Roivant Sciences Ltd. (company) — Registrant
- September 10, 2024 (date) — Earliest event reported
- September 16, 2024 (date) — Date of report
- Bermuda (location) — Jurisdiction of Incorporation
- London (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of the matters voted upon are not provided in this excerpt.
What financial statements and exhibits are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific contents are not detailed in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 10, 2024.
Where are Roivant Sciences Ltd.'s principal executive offices located?
Roivant Sciences Ltd.'s principal executive offices are located at 7th Floor 50 Broadway London SW1H 0DB United Kingdom.
What is the SIC code for Roivant Sciences Ltd.?
The Standard Industrial Classification (SIC) code for Roivant Sciences Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 760 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2024-09-16 17:05:33
Key Financial Figures
- $0.0000000341740141 — nge on which registered Common Shares, $0.0000000341740141 per share ROIV The Nasdaq Global Se
Filing Documents
- ef20035923_8k.htm (8-K) — 47KB
- 0001140361-24-041188.txt ( ) — 181KB
- roiv-20240910.xsd (EX-101.SCH) — 4KB
- roiv-20240910_lab.xml (EX-101.LAB) — 21KB
- roiv-20240910_pre.xml (EX-101.PRE) — 16KB
- ef20035923_8k_htm.xml (XML) — 4KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders. On September 10, 2024, Roivant Sciences Ltd. (the "Company") held its 2024 Annual General Meeting of Shareholders. At that meeting, the shareholders considered and acted upon four proposals as described in more detail in the Company's Proxy Statement. Of 739,183,842 common shares outstanding and entitled to vote as of the close of business on the record date for the meeting, July 17, 2024, the holders of record of 680,116,302 common shares were present at the meeting either in person or by proxy. All proposals on the agenda were approved by the shareholders. Below are the final voting results. (1) Shareholders re-elected the individuals named below to serve as Class III directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2027, and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal. Election of each director required approval by a plurality of the votes cast. Nominee For Withheld Broker Non-Votes Ilan Oren 409,647,664 195,587,109 74,881,529 James C. Momtazee 457,800,746 147,434,027 74,881,529 Dr. Mayukh Sukhatme 602,544,381 2,690,392 74,881,529 (2) Shareholders ratified the appointment of Ernst & Young LLP ("EY") to serve as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2025, and to appoint EY as the Company's auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for the fiscal year ending March 31, 2025. Ratification required a simple majority of the votes cast. For 679,096,310 Against 759,669 Abstain 260,323 (3) Shareholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures. For
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROIVANT SCIENCES LTD. Date: September 16, 2024 By: /s/ Matt Maisak Name: Matt Maisak Title: Authorized Signatory